English
简体中文
Total: £ 56.28
Published Date: 2024-04-07 | Pages: 138 | Tables: 242 | Pharma & Healthcare
Recombinant avian influenza virus (H5+H7) inactivated vaccine is suitable for a variety of target animals, including breeder hens, layer hens, broiler chickens, breeder ducks, geese, etc. According to the immunization schedule, the primary immunization of chicks, ducklings and goslings lasts The period is 2 months, and it can be used for emergency immunization against highly pathogenic avian influenza at the same time.
The global market for Reassortant Avian Influenza Virus Vaccine was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Reassortant Avian Influenza Virus Vaccine was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Reassortant Avian Influenza Virus Vaccine was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Reassortant Avian Influenza Virus Vaccine was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Reassortant Avian Influenza Virus Vaccine include Zoetis, Boehringer-Ingelheim, Eurovet, Merck Animal Health, BICR, China Animal Husbandry Industry, Weike Biotechnology, Ringpu and Guangdong Winsun Bio Pharmaceutical, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Reassortant Avian Influenza Virus Vaccine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Reassortant Avian Influenza Virus Vaccine by region & country, by Type, and by Application.
The Reassortant Avian Influenza Virus Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Reassortant Avian Influenza Virus Vaccine.
Market Segmentation
By Company
Zoetis
Boehringer-Ingelheim
Eurovet
Merck Animal Health
BICR
China Animal Husbandry Industry
Weike Biotechnology
Ringpu
Guangdong Winsun Bio Pharmaceutical
Pulike
QYH Biotech
YEBIO Bioengineering
Yikang Biological
DAHUANONG
Guangzhou South China Biological Medicine
Segment by Type:
Bivalent Inactivated Vaccine
Trivalent Inactivated Vaccine
Segment by Application
Piglets
Adults Pigs
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Reassortant Avian Influenza Virus Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Reassortant Avian Influenza Virus Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Reassortant Avian Influenza Virus Vaccine in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Market Overview
1.1 Reassortant Avian Influenza Virus Vaccine Product Introduction
1.2 Global Reassortant Avian Influenza Virus Vaccine Market Size Forecast
1.2.1 Global Reassortant Avian Influenza Virus Vaccine Sales Value (2019-2030)
1.2.2 Global Reassortant Avian Influenza Virus Vaccine Sales Volume (2019-2030)
1.2.3 Global Reassortant Avian Influenza Virus Vaccine Sales Price (2019-2030)
1.3 Reassortant Avian Influenza Virus Vaccine Market Trends & Drivers
1.3.1 Reassortant Avian Influenza Virus Vaccine Industry Trends
1.3.2 Reassortant Avian Influenza Virus Vaccine Market Drivers & Opportunity
1.3.3 Reassortant Avian Influenza Virus Vaccine Market Challenges
1.3.4 Reassortant Avian Influenza Virus Vaccine Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Reassortant Avian Influenza Virus Vaccine Players Revenue Ranking (2023)
2.2 Global Reassortant Avian Influenza Virus Vaccine Revenue by Company (2019-2024)
2.3 Global Reassortant Avian Influenza Virus Vaccine Players Sales Volume Ranking (2023)
2.4 Global Reassortant Avian Influenza Virus Vaccine Sales Volume by Company Players (2019-2024)
2.5 Global Reassortant Avian Influenza Virus Vaccine Average Price by Company (2019-2024)
2.6 Key Manufacturers Reassortant Avian Influenza Virus Vaccine Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Reassortant Avian Influenza Virus Vaccine Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Reassortant Avian Influenza Virus Vaccine
2.9 Reassortant Avian Influenza Virus Vaccine Market Competitive Analysis
2.9.1 Reassortant Avian Influenza Virus Vaccine Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Reassortant Avian Influenza Virus Vaccine Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Reassortant Avian Influenza Virus Vaccine as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Bivalent Inactivated Vaccine
3.1.2 Trivalent Inactivated Vaccine
3.2 Global Reassortant Avian Influenza Virus Vaccine Sales Value by Type
3.2.1 Global Reassortant Avian Influenza Virus Vaccine Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Reassortant Avian Influenza Virus Vaccine Sales Value, by Type (2019-2030)
3.2.3 Global Reassortant Avian Influenza Virus Vaccine Sales Value, by Type (%) (2019-2030)
3.3 Global Reassortant Avian Influenza Virus Vaccine Sales Volume by Type
3.3.1 Global Reassortant Avian Influenza Virus Vaccine Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Reassortant Avian Influenza Virus Vaccine Sales Volume, by Type (2019-2030)
3.3.3 Global Reassortant Avian Influenza Virus Vaccine Sales Volume, by Type (%) (2019-2030)
3.4 Global Reassortant Avian Influenza Virus Vaccine Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Piglets
4.1.2 Adults Pigs
4.2 Global Reassortant Avian Influenza Virus Vaccine Sales Value by Application
4.2.1 Global Reassortant Avian Influenza Virus Vaccine Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Reassortant Avian Influenza Virus Vaccine Sales Value, by Application (2019-2030)
4.2.3 Global Reassortant Avian Influenza Virus Vaccine Sales Value, by Application (%) (2019-2030)
4.3 Global Reassortant Avian Influenza Virus Vaccine Sales Volume by Application
4.3.1 Global Reassortant Avian Influenza Virus Vaccine Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Reassortant Avian Influenza Virus Vaccine Sales Volume, by Application (2019-2030)
4.3.3 Global Reassortant Avian Influenza Virus Vaccine Sales Volume, by Application (%) (2019-2030)
4.4 Global Reassortant Avian Influenza Virus Vaccine Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Reassortant Avian Influenza Virus Vaccine Sales Value by Region
5.1.1 Global Reassortant Avian Influenza Virus Vaccine Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Reassortant Avian Influenza Virus Vaccine Sales Value by Region (2019-2024)
5.1.3 Global Reassortant Avian Influenza Virus Vaccine Sales Value by Region (2025-2030)
5.1.4 Global Reassortant Avian Influenza Virus Vaccine Sales Value by Region (%), (2019-2030)
5.2 Global Reassortant Avian Influenza Virus Vaccine Sales Volume by Region
5.2.1 Global Reassortant Avian Influenza Virus Vaccine Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Reassortant Avian Influenza Virus Vaccine Sales Volume by Region (2019-2024)
5.2.3 Global Reassortant Avian Influenza Virus Vaccine Sales Volume by Region (2025-2030)
5.2.4 Global Reassortant Avian Influenza Virus Vaccine Sales Volume by Region (%), (2019-2030)
5.3 Global Reassortant Avian Influenza Virus Vaccine Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Reassortant Avian Influenza Virus Vaccine Sales Value, 2019-2030
5.4.2 North America Reassortant Avian Influenza Virus Vaccine Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Reassortant Avian Influenza Virus Vaccine Sales Value, 2019-2030
5.5.2 Europe Reassortant Avian Influenza Virus Vaccine Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Reassortant Avian Influenza Virus Vaccine Sales Value, 2019-2030
5.6.2 Asia Pacific Reassortant Avian Influenza Virus Vaccine Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Reassortant Avian Influenza Virus Vaccine Sales Value, 2019-2030
5.7.2 South America Reassortant Avian Influenza Virus Vaccine Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Reassortant Avian Influenza Virus Vaccine Sales Value, 2019-2030
5.8.2 Middle East & Africa Reassortant Avian Influenza Virus Vaccine Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Reassortant Avian Influenza Virus Vaccine Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Reassortant Avian Influenza Virus Vaccine Sales Value
6.2.1 Key Countries/Regions Reassortant Avian Influenza Virus Vaccine Sales Value, 2019-2030
6.2.2 Key Countries/Regions Reassortant Avian Influenza Virus Vaccine Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Reassortant Avian Influenza Virus Vaccine Sales Value, 2019-2030
6.3.2 United States Reassortant Avian Influenza Virus Vaccine Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Reassortant Avian Influenza Virus Vaccine Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Reassortant Avian Influenza Virus Vaccine Sales Value, 2019-2030
6.4.2 Europe Reassortant Avian Influenza Virus Vaccine Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Reassortant Avian Influenza Virus Vaccine Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Reassortant Avian Influenza Virus Vaccine Sales Value, 2019-2030
6.5.2 China Reassortant Avian Influenza Virus Vaccine Sales Value by Type (%), 2023 VS 2030
6.5.3 China Reassortant Avian Influenza Virus Vaccine Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Reassortant Avian Influenza Virus Vaccine Sales Value, 2019-2030
6.6.2 Japan Reassortant Avian Influenza Virus Vaccine Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Reassortant Avian Influenza Virus Vaccine Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Reassortant Avian Influenza Virus Vaccine Sales Value, 2019-2030
6.7.2 South Korea Reassortant Avian Influenza Virus Vaccine Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Reassortant Avian Influenza Virus Vaccine Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Reassortant Avian Influenza Virus Vaccine Sales Value, 2019-2030
6.8.2 Southeast Asia Reassortant Avian Influenza Virus Vaccine Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Reassortant Avian Influenza Virus Vaccine Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Reassortant Avian Influenza Virus Vaccine Sales Value, 2019-2030
6.9.2 India Reassortant Avian Influenza Virus Vaccine Sales Value by Type (%), 2023 VS 2030
6.9.3 India Reassortant Avian Influenza Virus Vaccine Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Zoetis
7.1.1 Zoetis Company Information
7.1.2 Zoetis Introduction and Business Overview
7.1.3 Zoetis Reassortant Avian Influenza Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Zoetis Reassortant Avian Influenza Virus Vaccine Product Offerings
7.1.5 Zoetis Recent Development
7.2 Boehringer-Ingelheim
7.2.1 Boehringer-Ingelheim Company Information
7.2.2 Boehringer-Ingelheim Introduction and Business Overview
7.2.3 Boehringer-Ingelheim Reassortant Avian Influenza Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Boehringer-Ingelheim Reassortant Avian Influenza Virus Vaccine Product Offerings
7.2.5 Boehringer-Ingelheim Recent Development
7.3 Eurovet
7.3.1 Eurovet Company Information
7.3.2 Eurovet Introduction and Business Overview
7.3.3 Eurovet Reassortant Avian Influenza Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Eurovet Reassortant Avian Influenza Virus Vaccine Product Offerings
7.3.5 Eurovet Recent Development
7.4 Merck Animal Health
7.4.1 Merck Animal Health Company Information
7.4.2 Merck Animal Health Introduction and Business Overview
7.4.3 Merck Animal Health Reassortant Avian Influenza Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Merck Animal Health Reassortant Avian Influenza Virus Vaccine Product Offerings
7.4.5 Merck Animal Health Recent Development
7.5 BICR
7.5.1 BICR Company Information
7.5.2 BICR Introduction and Business Overview
7.5.3 BICR Reassortant Avian Influenza Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.5.4 BICR Reassortant Avian Influenza Virus Vaccine Product Offerings
7.5.5 BICR Recent Development
7.6 China Animal Husbandry Industry
7.6.1 China Animal Husbandry Industry Company Information
7.6.2 China Animal Husbandry Industry Introduction and Business Overview
7.6.3 China Animal Husbandry Industry Reassortant Avian Influenza Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.6.4 China Animal Husbandry Industry Reassortant Avian Influenza Virus Vaccine Product Offerings
7.6.5 China Animal Husbandry Industry Recent Development
7.7 Weike Biotechnology
7.7.1 Weike Biotechnology Company Information
7.7.2 Weike Biotechnology Introduction and Business Overview
7.7.3 Weike Biotechnology Reassortant Avian Influenza Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Weike Biotechnology Reassortant Avian Influenza Virus Vaccine Product Offerings
7.7.5 Weike Biotechnology Recent Development
7.8 Ringpu
7.8.1 Ringpu Company Information
7.8.2 Ringpu Introduction and Business Overview
7.8.3 Ringpu Reassortant Avian Influenza Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Ringpu Reassortant Avian Influenza Virus Vaccine Product Offerings
7.8.5 Ringpu Recent Development
7.9 Guangdong Winsun Bio Pharmaceutical
7.9.1 Guangdong Winsun Bio Pharmaceutical Company Information
7.9.2 Guangdong Winsun Bio Pharmaceutical Introduction and Business Overview
7.9.3 Guangdong Winsun Bio Pharmaceutical Reassortant Avian Influenza Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Guangdong Winsun Bio Pharmaceutical Reassortant Avian Influenza Virus Vaccine Product Offerings
7.9.5 Guangdong Winsun Bio Pharmaceutical Recent Development
7.10 Pulike
7.10.1 Pulike Company Information
7.10.2 Pulike Introduction and Business Overview
7.10.3 Pulike Reassortant Avian Influenza Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Pulike Reassortant Avian Influenza Virus Vaccine Product Offerings
7.10.5 Pulike Recent Development
7.11 QYH Biotech
7.11.1 QYH Biotech Company Information
7.11.2 QYH Biotech Introduction and Business Overview
7.11.3 QYH Biotech Reassortant Avian Influenza Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.11.4 QYH Biotech Reassortant Avian Influenza Virus Vaccine Product Offerings
7.11.5 QYH Biotech Recent Development
7.12 YEBIO Bioengineering
7.12.1 YEBIO Bioengineering Company Information
7.12.2 YEBIO Bioengineering Introduction and Business Overview
7.12.3 YEBIO Bioengineering Reassortant Avian Influenza Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.12.4 YEBIO Bioengineering Reassortant Avian Influenza Virus Vaccine Product Offerings
7.12.5 YEBIO Bioengineering Recent Development
7.13 Yikang Biological
7.13.1 Yikang Biological Company Information
7.13.2 Yikang Biological Introduction and Business Overview
7.13.3 Yikang Biological Reassortant Avian Influenza Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Yikang Biological Reassortant Avian Influenza Virus Vaccine Product Offerings
7.13.5 Yikang Biological Recent Development
7.14 DAHUANONG
7.14.1 DAHUANONG Company Information
7.14.2 DAHUANONG Introduction and Business Overview
7.14.3 DAHUANONG Reassortant Avian Influenza Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.14.4 DAHUANONG Reassortant Avian Influenza Virus Vaccine Product Offerings
7.14.5 DAHUANONG Recent Development
7.15 Guangzhou South China Biological Medicine
7.15.1 Guangzhou South China Biological Medicine Company Information
7.15.2 Guangzhou South China Biological Medicine Introduction and Business Overview
7.15.3 Guangzhou South China Biological Medicine Reassortant Avian Influenza Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.15.4 Guangzhou South China Biological Medicine Reassortant Avian Influenza Virus Vaccine Product Offerings
7.15.5 Guangzhou South China Biological Medicine Recent Development
8 Industry Chain Analysis
8.1 Reassortant Avian Influenza Virus Vaccine Industrial Chain
8.2 Reassortant Avian Influenza Virus Vaccine Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Reassortant Avian Influenza Virus Vaccine Sales Model
8.5.2 Sales Channel
8.5.3 Reassortant Avian Influenza Virus Vaccine Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Reassortant Avian Influenza Virus Vaccine Market Trends
Table 2. Reassortant Avian Influenza Virus Vaccine Market Drivers & Opportunity
Table 3. Reassortant Avian Influenza Virus Vaccine Market Challenges
Table 4. Reassortant Avian Influenza Virus Vaccine Market Restraints
Table 5. Global Reassortant Avian Influenza Virus Vaccine Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Reassortant Avian Influenza Virus Vaccine Revenue Market Share by Company (2019-2024)
Table 7. Global Reassortant Avian Influenza Virus Vaccine Sales Volume by Company (2019-2024) & (K Doses)
Table 8. Global Reassortant Avian Influenza Virus Vaccine Sales Volume Market Share by Company (2019-2024)
Table 9. Global Market Reassortant Avian Influenza Virus Vaccine Price by Company (2019-2024) & (US$/Dose)
Table 10. Key Manufacturers Reassortant Avian Influenza Virus Vaccine Manufacturing Base Distribution and Headquarters
Table 11. Key Manufacturers Reassortant Avian Influenza Virus Vaccine Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Reassortant Avian Influenza Virus Vaccine
Table 13. Global Reassortant Avian Influenza Virus Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Reassortant Avian Influenza Virus Vaccine as of 2023)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Reassortant Avian Influenza Virus Vaccine Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Reassortant Avian Influenza Virus Vaccine Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Reassortant Avian Influenza Virus Vaccine Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Reassortant Avian Influenza Virus Vaccine Sales Market Share in Value by Type (2019-2024) & (%)
Table 20. Global Reassortant Avian Influenza Virus Vaccine Sales Market Share in Value by Type (2025-2030) & (%)
Table 21. Global Reassortant Avian Influenza Virus Vaccine Sales Volume by Type: 2019 VS 2023 VS 2030 (K Doses)
Table 22. Global Reassortant Avian Influenza Virus Vaccine Sales Volume by Type (2019-2024) & (K Doses)
Table 23. Global Reassortant Avian Influenza Virus Vaccine Sales Volume by Type (2025-2030) & (K Doses)
Table 24. Global Reassortant Avian Influenza Virus Vaccine Sales Market Share in Volume by Type (2019-2024) & (%)
Table 25. Global Reassortant Avian Influenza Virus Vaccine Sales Market Share in Volume by Type (2025-2030) & (%)
Table 26. Global Reassortant Avian Influenza Virus Vaccine Price by Type (2019-2024) & (US$/Dose)
Table 27. Global Reassortant Avian Influenza Virus Vaccine Price by Type (2025-2030) & (US$/Dose)
Table 28. Global Reassortant Avian Influenza Virus Vaccine Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Reassortant Avian Influenza Virus Vaccine Sales Value by Application (2019-2024) & (US$ Million)
Table 30. Global Reassortant Avian Influenza Virus Vaccine Sales Value by Application (2025-2030) & (US$ Million)
Table 31. Global Reassortant Avian Influenza Virus Vaccine Sales Market Share in Value by Application (2019-2024) & (%)
Table 32. Global Reassortant Avian Influenza Virus Vaccine Sales Market Share in Value by Application (2025-2030) & (%)
Table 33. Global Reassortant Avian Influenza Virus Vaccine Sales Volume by Application: 2019 VS 2023 VS 2030 (K Doses)
Table 34. Global Reassortant Avian Influenza Virus Vaccine Sales Volume by Application (2019-2024) & (K Doses)
Table 35. Global Reassortant Avian Influenza Virus Vaccine Sales Volume by Application (2025-2030) & (K Doses)
Table 36. Global Reassortant Avian Influenza Virus Vaccine Sales Market Share in Volume by Application (2019-2024) & (%)
Table 37. Global Reassortant Avian Influenza Virus Vaccine Sales Market Share in Volume by Application (2025-2030) & (%)
Table 38. Global Reassortant Avian Influenza Virus Vaccine Price by Application (2019-2024) & (US$/Dose)
Table 39. Global Reassortant Avian Influenza Virus Vaccine Price by Application (2025-2030) & (US$/Dose)
Table 40. Global Reassortant Avian Influenza Virus Vaccine Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Reassortant Avian Influenza Virus Vaccine Sales Value by Region (2019-2024) & (US$ Million)
Table 42. Global Reassortant Avian Influenza Virus Vaccine Sales Value by Region (2025-2030) & (US$ Million)
Table 43. Global Reassortant Avian Influenza Virus Vaccine Sales Value by Region (2019-2024) & (%)
Table 44. Global Reassortant Avian Influenza Virus Vaccine Sales Value by Region (2025-2030) & (%)
Table 45. Global Reassortant Avian Influenza Virus Vaccine Sales Volume by Region (K Doses): 2019 VS 2023 VS 2030
Table 46. Global Reassortant Avian Influenza Virus Vaccine Sales Volume by Region (2019-2024) & (K Doses)
Table 47. Global Reassortant Avian Influenza Virus Vaccine Sales Volume by Region (2025-2030) & (K Doses)
Table 48. Global Reassortant Avian Influenza Virus Vaccine Sales Volume by Region (2019-2024) & (%)
Table 49. Global Reassortant Avian Influenza Virus Vaccine Sales Volume by Region (2025-2030) & (%)
Table 50. Global Reassortant Avian Influenza Virus Vaccine Average Price by Region (2019-2024) & (US$/Dose)
Table 51. Global Reassortant Avian Influenza Virus Vaccine Average Price by Region (2025-2030) & (US$/Dose)
Table 52. Key Countries/Regions Reassortant Avian Influenza Virus Vaccine Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 53. Key Countries/Regions Reassortant Avian Influenza Virus Vaccine Sales Value, (2019-2024) & (US$ Million)
Table 54. Key Countries/Regions Reassortant Avian Influenza Virus Vaccine Sales Value, (2025-2030) & (US$ Million)
Table 55. Key Countries/Regions Reassortant Avian Influenza Virus Vaccine Sales Volume, (2019-2024) & (K Doses)
Table 56. Key Countries/Regions Reassortant Avian Influenza Virus Vaccine Sales Volume, (2025-2030) & (K Doses)
Table 57. Zoetis Company Information
Table 58. Zoetis Introduction and Business Overview
Table 59. Zoetis Reassortant Avian Influenza Virus Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 60. Zoetis Reassortant Avian Influenza Virus Vaccine Product Offerings
Table 61. Zoetis Recent Development
Table 62. Boehringer-Ingelheim Company Information
Table 63. Boehringer-Ingelheim Introduction and Business Overview
Table 64. Boehringer-Ingelheim Reassortant Avian Influenza Virus Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 65. Boehringer-Ingelheim Reassortant Avian Influenza Virus Vaccine Product Offerings
Table 66. Boehringer-Ingelheim Recent Development
Table 67. Eurovet Company Information
Table 68. Eurovet Introduction and Business Overview
Table 69. Eurovet Reassortant Avian Influenza Virus Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 70. Eurovet Reassortant Avian Influenza Virus Vaccine Product Offerings
Table 71. Eurovet Recent Development
Table 72. Merck Animal Health Company Information
Table 73. Merck Animal Health Introduction and Business Overview
Table 74. Merck Animal Health Reassortant Avian Influenza Virus Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 75. Merck Animal Health Reassortant Avian Influenza Virus Vaccine Product Offerings
Table 76. Merck Animal Health Recent Development
Table 77. BICR Company Information
Table 78. BICR Introduction and Business Overview
Table 79. BICR Reassortant Avian Influenza Virus Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 80. BICR Reassortant Avian Influenza Virus Vaccine Product Offerings
Table 81. BICR Recent Development
Table 82. China Animal Husbandry Industry Company Information
Table 83. China Animal Husbandry Industry Introduction and Business Overview
Table 84. China Animal Husbandry Industry Reassortant Avian Influenza Virus Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 85. China Animal Husbandry Industry Reassortant Avian Influenza Virus Vaccine Product Offerings
Table 86. China Animal Husbandry Industry Recent Development
Table 87. Weike Biotechnology Company Information
Table 88. Weike Biotechnology Introduction and Business Overview
Table 89. Weike Biotechnology Reassortant Avian Influenza Virus Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 90. Weike Biotechnology Reassortant Avian Influenza Virus Vaccine Product Offerings
Table 91. Weike Biotechnology Recent Development
Table 92. Ringpu Company Information
Table 93. Ringpu Introduction and Business Overview
Table 94. Ringpu Reassortant Avian Influenza Virus Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 95. Ringpu Reassortant Avian Influenza Virus Vaccine Product Offerings
Table 96. Ringpu Recent Development
Table 97. Guangdong Winsun Bio Pharmaceutical Company Information
Table 98. Guangdong Winsun Bio Pharmaceutical Introduction and Business Overview
Table 99. Guangdong Winsun Bio Pharmaceutical Reassortant Avian Influenza Virus Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 100. Guangdong Winsun Bio Pharmaceutical Reassortant Avian Influenza Virus Vaccine Product Offerings
Table 101. Guangdong Winsun Bio Pharmaceutical Recent Development
Table 102. Pulike Company Information
Table 103. Pulike Introduction and Business Overview
Table 104. Pulike Reassortant Avian Influenza Virus Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 105. Pulike Reassortant Avian Influenza Virus Vaccine Product Offerings
Table 106. Pulike Recent Development
Table 107. QYH Biotech Company Information
Table 108. QYH Biotech Introduction and Business Overview
Table 109. QYH Biotech Reassortant Avian Influenza Virus Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 110. QYH Biotech Reassortant Avian Influenza Virus Vaccine Product Offerings
Table 111. QYH Biotech Recent Development
Table 112. YEBIO Bioengineering Company Information
Table 113. YEBIO Bioengineering Introduction and Business Overview
Table 114. YEBIO Bioengineering Reassortant Avian Influenza Virus Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 115. YEBIO Bioengineering Reassortant Avian Influenza Virus Vaccine Product Offerings
Table 116. YEBIO Bioengineering Recent Development
Table 117. Yikang Biological Company Information
Table 118. Yikang Biological Introduction and Business Overview
Table 119. Yikang Biological Reassortant Avian Influenza Virus Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 120. Yikang Biological Reassortant Avian Influenza Virus Vaccine Product Offerings
Table 121. Yikang Biological Recent Development
Table 122. DAHUANONG Company Information
Table 123. DAHUANONG Introduction and Business Overview
Table 124. DAHUANONG Reassortant Avian Influenza Virus Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 125. DAHUANONG Reassortant Avian Influenza Virus Vaccine Product Offerings
Table 126. DAHUANONG Recent Development
Table 127. Guangzhou South China Biological Medicine Company Information
Table 128. Guangzhou South China Biological Medicine Introduction and Business Overview
Table 129. Guangzhou South China Biological Medicine Reassortant Avian Influenza Virus Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 130. Guangzhou South China Biological Medicine Reassortant Avian Influenza Virus Vaccine Product Offerings
Table 131. Guangzhou South China Biological Medicine Recent Development
Table 132. Key Raw Materials Lists
Table 133. Raw Materials Key Suppliers Lists
Table 134. Reassortant Avian Influenza Virus Vaccine Downstream Customers
Table 135. Reassortant Avian Influenza Virus Vaccine Distributors List
Table 136. Research Programs/Design for This Report
Table 137. Key Data Information from Secondary Sources
Table 138. Key Data Information from Primary Sources
List of Figures
Figure 1. Reassortant Avian Influenza Virus Vaccine Product Picture
Figure 2. Global Reassortant Avian Influenza Virus Vaccine Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Reassortant Avian Influenza Virus Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Reassortant Avian Influenza Virus Vaccine Sales Volume (2019-2030) & (K Doses)
Figure 5. Global Reassortant Avian Influenza Virus Vaccine Sales Price (2019-2030) & (US$/Dose)
Figure 6. Reassortant Avian Influenza Virus Vaccine Report Years Considered
Figure 7. Global Reassortant Avian Influenza Virus Vaccine Players Revenue Ranking (2023) & (US$ Million)
Figure 8. Global Reassortant Avian Influenza Virus Vaccine Players Sales Volume Ranking (2023) & (K Doses)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Reassortant Avian Influenza Virus Vaccine Revenue in 2023
Figure 10. Reassortant Avian Influenza Virus Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 11. Bivalent Inactivated Vaccine Picture
Figure 12. Trivalent Inactivated Vaccine Picture
Figure 13. Global Reassortant Avian Influenza Virus Vaccine Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 14. Global Reassortant Avian Influenza Virus Vaccine Sales Value Market Share by Type, 2023 & 2030
Figure 15. Global Reassortant Avian Influenza Virus Vaccine Sales Volume by Type (2019 VS 2023 VS 2030) & (K Doses)
Figure 16. Global Reassortant Avian Influenza Virus Vaccine Sales Volume Market Share by Type, 2023 & 2030
Figure 17. Global Reassortant Avian Influenza Virus Vaccine Price by Type (2019-2030) & (US$/Dose)
Figure 18. Product Picture of Piglets
Figure 19. Product Picture of Adults Pigs
Figure 20. Global Reassortant Avian Influenza Virus Vaccine Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 21. Global Reassortant Avian Influenza Virus Vaccine Sales Value Market Share by Application, 2023 & 2030
Figure 22. Global Reassortant Avian Influenza Virus Vaccine Sales Volume by Application (2019 VS 2023 VS 2030) & (K Doses)
Figure 23. Global Reassortant Avian Influenza Virus Vaccine Sales Volume Market Share by Application, 2023 & 2030
Figure 24. Global Reassortant Avian Influenza Virus Vaccine Price by Application (2019-2030) & (US$/Dose)
Figure 25. North America Reassortant Avian Influenza Virus Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 26. North America Reassortant Avian Influenza Virus Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 27. Europe Reassortant Avian Influenza Virus Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 28. Europe Reassortant Avian Influenza Virus Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 29. Asia Pacific Reassortant Avian Influenza Virus Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 30. Asia Pacific Reassortant Avian Influenza Virus Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 31. South America Reassortant Avian Influenza Virus Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 32. South America Reassortant Avian Influenza Virus Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 33. Middle East & Africa Reassortant Avian Influenza Virus Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 34. Middle East & Africa Reassortant Avian Influenza Virus Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 35. Key Countries/Regions Reassortant Avian Influenza Virus Vaccine Sales Value (%), (2019-2030)
Figure 36. Key Countries/Regions Reassortant Avian Influenza Virus Vaccine Sales Volume (%), (2019-2030)
Figure 37. United States Reassortant Avian Influenza Virus Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 38. United States Reassortant Avian Influenza Virus Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 39. United States Reassortant Avian Influenza Virus Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 40. Europe Reassortant Avian Influenza Virus Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 41. Europe Reassortant Avian Influenza Virus Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 42. Europe Reassortant Avian Influenza Virus Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 43. China Reassortant Avian Influenza Virus Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 44. China Reassortant Avian Influenza Virus Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 45. China Reassortant Avian Influenza Virus Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 46. Japan Reassortant Avian Influenza Virus Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 47. Japan Reassortant Avian Influenza Virus Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 48. Japan Reassortant Avian Influenza Virus Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 49. South Korea Reassortant Avian Influenza Virus Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 50. South Korea Reassortant Avian Influenza Virus Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 51. South Korea Reassortant Avian Influenza Virus Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 52. Southeast Asia Reassortant Avian Influenza Virus Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 53. Southeast Asia Reassortant Avian Influenza Virus Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 54. Southeast Asia Reassortant Avian Influenza Virus Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 55. India Reassortant Avian Influenza Virus Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 56. India Reassortant Avian Influenza Virus Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 57. India Reassortant Avian Influenza Virus Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 58. Reassortant Avian Influenza Virus Vaccine Industrial Chain
Figure 59. Reassortant Avian Influenza Virus Vaccine Manufacturing Cost Structure
Figure 60. Channels of Distribution (Direct Sales, and Distribution)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
